Wed, November 27, 2024
Tue, November 26, 2024
Mon, November 25, 2024
Thu, November 14, 2024
Tue, November 12, 2024
Sat, June 10, 2017
Sat, June 3, 2017
Wed, May 31, 2017
Wed, May 17, 2017
Fri, May 12, 2017
Thu, May 11, 2017
Tue, May 9, 2017
Thu, May 4, 2017
Thu, April 20, 2017
Fri, April 14, 2017
Thu, March 23, 2017
Fri, March 17, 2017
Thu, March 9, 2017
Sat, March 4, 2017
Fri, March 3, 2017
Thu, March 2, 2017
Wed, February 15, 2017
Mon, February 13, 2017
Wed, February 8, 2017
Thu, February 2, 2017
Fri, January 13, 2017
Wed, January 11, 2017
Wed, January 4, 2017
Fri, December 16, 2016
Thu, December 15, 2016
Mon, December 12, 2016
Thu, December 8, 2016
Wed, November 23, 2016
Mon, November 14, 2016
Sun, November 13, 2016
Wed, November 9, 2016
Thu, November 3, 2016
Wed, November 2, 2016
Mon, October 17, 2016
Sat, October 8, 2016
Thu, October 6, 2016
Wed, October 5, 2016
Mon, October 3, 2016
Fri, September 30, 2016
Thu, September 29, 2016
Tue, September 27, 2016
Mon, September 26, 2016
Fri, September 23, 2016
Thu, September 22, 2016
Wed, September 21, 2016
[ Wed, Sep 21st 2016 ] - Market Wire
Last Patient Out
Tue, September 20, 2016
Mon, September 19, 2016
Sun, September 18, 2016
Fri, September 16, 2016
Thu, September 15, 2016
Wed, September 14, 2016
Mon, September 12, 2016
Fri, September 9, 2016
Thu, May 9, 2013
[ Thu, May 09th 2013 ] - Market Wire
Achieves Record Revenues
Wed, May 8, 2013
Tue, May 7, 2013
Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013

Morgan amp;; Morgan Announces the Investigation of Chemed Corporation (NYSE: CHE)


//health-fitness.news-articles.net/content/2013/ .. nvestigation-of-chemed-corporation-nyse-che.html
Published in Health and Fitness on Wednesday, May 8th 2013 at 10:15 GMT by Market Wire   Print publication without navigation


Morgan & Morgan Announces the Investigation of Chemed Corporation (NYSE: CHE) -- NEW YORK, May 8, 2013 /PRNewswire/ --

NEW YORK, May 8, 2013 /PRNewswire/ -- Morgan & Morgan announces that it is investigating possible securities law violations by Chemed Corporation ("Chemed" or the "Company") (NYSE:  CHE) following the U.S. Department of Justice's ("DOJ") filing of a lawsuit alleging that Chemed's Vitas Hospice units ("Vitas") knowingly overbilled the Government's Medicare program.   

If you purchased Chemed and want more information about the [ Chemed securities fraud class action ], please contact George Pressly, Esq. at 1 (800) 631-6234 or email George at [ AskGeorge@morgansecuritieslaw.com ].

Specifically, the DOJ complaint alleges that Chemed and Vitas (collective, the "companies") knowingly submitted, or caused the submission of, false claims to Medicare for crisis care services that were either not necessary, not actually provided, or not performed in accordance with Medicare requirements.   According to the DOJ's complaint, the companies allegedly used aggressive marketing tactics and pressured staff to increase the numbers of crisis care claims submitted to Medicare without regard to whether the services were appropriate or were actually being provided.  In addition, the DOJ alleges that the companies knowingly submitted, or caused the submission, of false claims for hospice care for patients who were not terminally ill.    

As a result of the conduct alleged in the DOJ complaint, the government contends that the companies violated the False Claims Act and misspent tens of millions of taxpayer dollars from the Medicare program.

Morgan & Morgan's investigation is focused on the time period between May 2, 2008 and May 2, 2013 to determine primarily whether Chemed or its officers and directors violated the federal securities laws by artificially and materially inflating its financial results. 

Morgan & Morgan

Morgan & Morgan is one of the nation's largest 200 law firms. In addition to [ securities fraud ], the firm also practices in the areas of antitrust, [ consumer class actions ], personal injury, consumer protection, overtime, and product liability.  All of the Firm's legal endeavors are rooted in its core mission: provide investor and consumer protection and always fight "for the people." 

Attorney advertising. Prior results do not guarantee a similar outcome.

Contact:
Morgan & Morgan
Peter Safirstein, Esq.
28 West 44th Street
Suite 2001
New York, NY 10036
1-800-631-6234
[ info@morgansecuritieslaw.com ]

SOURCE Morgan & Morgan



RELATED LINKS
[ http://www.securitieslawfirm.com ]

Publication Contributing Sources